

The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor

Atsushi Mizokami,¹ Eitetsu Koh,¹ Hiroshi Fujita¹, Yuji Maeda¹, Masayuki Egawa,¹ Kiyoshi Koshida,¹ Seijiro Honma,² Evan T. Keller,³ and Mikio Namiki¹

¹Department of Urology, Kanazawa University, Kanazawa, Japan; ²Teikoku Hormone MFG. Co., Kanagawa, Japan; and ³Unit for Laboratory Animal Medicine and Department of Pathology, University of Michigan, Ann Arbor, Michigan

ABSTRACT

Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from an androgen-dependent to an androgen-independent phenotype. One of the mechanisms of relapse is antiandrogen withdrawal phenomenon caused by mutation of 877th amino acid of androgen receptor (AR). In the present study, we established a method to measure the concentration of androstenediol (adiol) in prostate tissue. We found that adiol maintains a high concentration in PCa tissue even after androgen deprivation therapy. Furthermore, adiol is a stronger activator of mutant AR in LNCaP PCa cells and induces more cell proliferation, prostate-specific antigen (PSA) mRNA expression, and PSA promoter than dihydrotestosterone (DHT). Because antiandrogen, bicalutamide, blocked adiol activity in LNCaP cells, it was suggested that adiol effect was mediated through AR. However, high concentration of bicalutamide was necessary to block completely adiol activity. These effects were specific to LNCaP cells because adiol had less effect in PC-3 PCa cells transfected with wild-type AR than DHT and had similar effect in PC-3 cells transfected with mutant AR. The mechanism that adiol activates mutant AR in LNCaP cells did not result from the increased affinity to mutant AR or from AR's association with coactivator ARA70. However, low concentration of adiol induced more AR nuclear translocation than DHT in LNCaP cells and not PC-3 cells transfected with AR. These results indicate that adiol may cause the progression of PCa even after hormone therapy.

INTRODUCTION

Prostate cancer (PCa) is the most common malignancy and the second most frequent cause of cancer-related death of men in the United States (1). Because PCa depends initially on androgens for growth, androgen deprivation therapies (usually some combination of orchiectomy, luteinizing hormone-releasing hormone analogues, and antiandrogens) often are the first choice of several therapeutic procedures for advanced PCa. The initial response rate to androgen deprivation therapy is 80–90%. However, the cancer reoccurs eventually and is considered to be androgen independent. The molecular mechanisms that account for the development to apparent androgen independence after the initiation of androgen deprivation therapy remain unclear. The observation that heterogeneity of androgen receptor (AR) expression in PCa correlates with malignancy suggests that androgen responsiveness plays an important key role in the progression of PCa (2).

Dehydroepiandrosterone (DHEA) accounts for the majority of androgen secreted from the adrenal gland. DHEA is converted in several cell types, including prostate epithelial cells, to androst-5-ene-3 β , 17 β -diol [Δ^5 -androstenediol (adiol)]. The concentration of adiol in plasma is ~ 1.5 ng/ml (5.2×10^{-9} M). Orchiectomy reduces the plasma concentration of testosterone (T) by >90%, but it reduces

adiol plasma concentration by only 50% (3). Although we have identified that adiol is the major metabolite of DHEA in human prostate homogenate *in vitro* (4), adiol levels in PCa tissues postorchiectomy have not been reported. This may be important to the progression of PCa because in addition to being converted to T and dihydrotestosterone (DHT), which activate the AR, adiol itself activates the AR (5).

On the basis of adiol's ability to activate the AR and its presence in prostate tissues, we explored the hypothesis that adiol provides androgenic stimulation of PCa even after androgen deprivation therapy. In the present study, we demonstrate that although DHT levels decrease, adiol levels are unchanged in PCa tissues after androgen deprivation therapy. Furthermore, we show that adiol is stronger than DHT at activating a mutated AR in a PCa cell line.

MATERIALS AND METHODS

Quantitative Analysis of Adiol and DHT in the Prostate. Benign prostate hypertrophy tissues without any hormonal treatments ($n = 15$) and PCa tissues with neoadjuvant hormone therapies for 3–6 months before radical prostatectomy ($n = 12$) were obtained from patients, who gave informed consent at Kanazawa University Hospital. Neoadjuvant hormone therapies were combinations of luteinizing hormone-releasing hormone agonist and antiandrogen drugs [chlormadinone acetate (two patients), hydroxyflutamide (seven patients), estramustine phosphate (one patient), or bicalutamide (two patients)]. The steroid concentration in prostate tissues was measured according to Shibata *et al.* (6). The powdered prostate was weighed for estimation of the tissue amount used for the analysis and then homogenized in 3 ml of distilled water using an Ultra-Turrax homogenizer (IKA, Staufen, Germany) on ice. Five ng of androstenediol-²H₄, 5 ng of T-19-C²H₃, and 5 ng of [17,16,16-²H₃]-DHT were added as internal standards to the individual homogenized sample, which then was extracted with 20 ml of 40% ethylacetate/n-hexane twice. The collected organic layer was washed with 5% NaHCO₃ and distilled water and then dried over anhydrous Na₂SO₄. The extracts were dissolved after evaporation in 1 ml of 30% acetonitrile/H₂O in an ultrasonic bath and applied to a 3-ml Bond Elut C18 cartridge column (Varian, Harbor City, CA). These columns then were washed with 3 ml of 30% acetonitrile/H₂O, and the steroidal fraction was eluted with 2.5 ml of 70% acetonitrile/H₂O and dried using a centrifugal evaporator. The extract was divided into adiol fraction, T, and DHT fraction, respectively. The dried DHT and T fractions were reacted with 100 μ l of carboxymethylamine hemihydrochloride solution (carboxymethylamine hemihydrochloride in pyridine, 2 mg/ml) overnight in the dark at room temperature. The carboxymethylamine hemihydrochloride derivatives in 0.02 N HCl solution were applied to a 3-ml Bond Elut C18 cartridge column. The columns were washed successively with 3 ml of distilled water and 6 ml of methanol/0.5% acetic acid (1:1), and the steroidal fraction then was eluted with 3 ml of methanol/H₂O (2:1). The collected fraction was evaporated to dryness; the obtained samples were dissolved in 100 μ l of high-performance liquid chromatography solvent; and 50 μ l was applied to a liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrument as described earlier. For DHT, the molecular ion mass of 364 m/z was cleaved again, and the produced ion mass of 270 m/z was monitored. The produced ion mass monitored for internal standards T-19-C²H₃ and [17,16,16-²H₃]-DHT were 271 and 273 m/z , respectively. The assay was validated to ensure that the result was within the 20% range of accuracy and precision. The lower limit values were 65 pg for DHT and T. Adiol fraction was treated with pyridine (50 μ l) and acetic anhydride (50 μ l) overnight at room temperature.

Received 1/22/03; revised 10/23/03; accepted 11/10/03.

Grant Support: DOD Grant PC020102.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Atsushi Mizokami, Department of Urology, Kanazawa University, 13-1 Takaramachi Kanazawa-city, 920-8640 Japan. Phone: 81-76-265-2393; Fax: 81-76-222-6726; E-mail: mizokami@med.kanazawa-u.ac.jp.

After evaporation of the solution, the sample was dissolved in 100 μ l of high-performance liquid chromatography solvent, and 50 μ l was applied to an LC-MS/MS instrument. The product ion, 255.2 m/z (259.2 m/z for the internal standard), was monitored for determination. The assay was validated to ensure that the result was within the 20% range of accuracy and precision. The lower limit values were 300 pg for adiol diacetate.

The plasma T level was estimated by LC-MS/MS using T- 2 H $_3$ as an internal standard. The plasma (100 μ l) that involved in an internal standard (1 ng) was extracted with ether, followed by treatment with 1-methyl-2-fluoropyridine to T-17-O-1'-methylpyridinium derivative. After the derivative was purified on a cartridge column, a part of the derivative was applied to an LC-MS/MS. Analytical ions were used with 253 m/z and 256 m/z produced from the molecular ions, respectively. The determination lower limit was 10 pg (50 pg/ml) for T. The plasma adiol level also was estimated by LC-MS/MS as described earlier.

Cell Culture and Cell Proliferation Assay. LNCaP cells were cultured in DMEM containing 5% FCS and penicillin/streptomycin (Invitrogen, Carlsbad, CA). Cell proliferation assay was performed by plating 1×10^5 cells on six-well plates in DMEM-5% charcoal-stripped FCS. Twenty-four h later, cells were treated with the indicated concentration of T, DHEA, DHT, androstenedione (4-dione), or adiol (Sigma, St. Louis, MO) and cultured for an additional 4 days. Media and reagents were replaced after 2 days. At the end of the culture period, the cells were trypsinized and counted with a hemocytometer.

RNA Extraction and Reverse Transcription-PCR. Twenty-four h after plating of 5×10^5 LNCaP cells, cells were treated with the indicated concentration of DHEA, DHT, 4-dione, or adiol for 12 h. Total RNA was purified with RNeasy mini kit (Qiagen, Valencia, CA). cDNA was made by reverse transcription of 1 μ g of each total RNA using ThermoScript reverse transcription-PCR system (Invitrogen). Each cDNA sample was amplified with ExTaq (Takara, Tokyo, Japan). PCR reaction for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and prostate-specific antigen (PSA); 94°C for 15 s, 56°C for 30 s, and 72°C for 30 s) was carried out using the following forward and reverse primers to detect GAPDH and PSA. The primer pairs were PSA-forward, 5'-GCCTCTCGTGGCAGGCAGT-3'; PSA-reverse, 5'-CTGAGGGTGAACCTGGGCAC-3'; GAPDH-forward, 5'-GACCACAGTCCATGC-CATCA-3'; and GAPDH-reverse, 5'-TCCACCACCCTGTTGCTGTA-3'. Each of the amplified products for PSA and GAPDH was determined by electrophoresis on a 1.5% agarose gel.

Scatchard Analysis. [1,2,4,5,6,7- 3 H]-5 α -DHT (specific activity 4007 Gbq/mmol) was obtained from New England Nuclear (Boston, MA). [1,2,6,7- 3 H]-androst-5-ene-3 β , 17 β -diol(3 H- Δ^5 -adiol) (specific activity 2220 Gbq/mmol) was synthesized from [1,2,6,7- 3 H]-DHEA by reduction of NaBH $_4$ in methanol at 4°C and then purified by liquid chromatography. Radioinert DHT and adiol were obtained from Steraloids, Inc. (Wilton, NH). Confluent cultures were scraped, homogenated in ice-cold hypertonic buffer [300 mM KCl, 10 mM Tris, 1.5 mM EDTA, 5 mM DTT, and 10 mM sodium molybdate, (pH 7.4)], and disrupted by sonication. The soluble extracts were prepared by ultracentrifugation at 105,000 $\times g$ for 30 min at 4°C. Scatchard analysis for DHT and adiol were determined based on the data from total binding and nonspecific binding assay. For total binding, extracts (250 μ l) were incubated in duplicate with seven steps of increasing concentrations of [3 H]-DHT (0.05–3.65 nM) or [3 H]adiol (0.058–3.7 nM) for 18 h. Nonspecific binding was carried out by addition of 250-fold excess unlabeled T and adiol, respectively, to the hot tubes including seven steps of increasing concentration of each labeled compound. Bound and free hormones were separated by the dextran-coated charcoal method described by Green and Leake (7). After incubating, 500 μ l of dextran-coated charcoal (final concentration 0.25% charcoal, 0.025% dextrane-T-70 in buffer) were added to each assay tube for total binding or nonspecific binding. After centrifugation to pellet the charcoal at 1200 $\times g$ for 10 min, 0.5 ml supernatant of total and nonspecific binding tubes was assayed for radiolabeled binding to protein. Specific binding was calculated by subtracting nonspecific binding obtained in the presence of excess of T or adiol from total binding measured in the absence of radioinert steroids.

Transfection and Luciferase Assay. Twenty-four h after plating 2×10^5 cells on six-well plates in DMEM-5% charcoal-stripped FCS, LNCaP cells were transfected by calcium phosphate precipitation with 1 μ g of luciferase reporter plasmid, pGLPSAp5.8, driven by 5.8 kb PSA promoter (9), 0.2 μ g β -galactosidase expression plasmid, and 1 μ g of pBluescript plasmid (Stratagene, La Jolla, CA) to serve as a carrier. For transfection of PC-3 cells, human

AR expression plasmid, pCMV-AR or pCMV-ARmut877 (kindly provided by Chawnsang Chang, University of Rochester, Rochester, NY), was cotransfected instead of pBluescript. Twenty-four h after transfection, the medium was changed, and cells were treated with the indicated concentration of T, DHEA, DHT, 4-dione, or adiol. Cells were harvested 24 h after addition of reagents and lysed in luciferase lysis buffer (Promega, Madison, WI). The luciferase activity was quantitated by a microplate luminometer, and the results were normalized by β -galactosidase activity.

Western Blot Analysis. Twenty-four h after plating 1×10^6 LNCaP or 7×10^5 PC-3 cells on 6-cm dishes in DMEM-5% charcoal-stripped FCS, the cells were treated with indicated concentration of DHT or adiol and harvested. After plating 7×10^5 PC-3 cells, cells were transfected with 4 μ g pCMV-AR or pCMV-ARmut877 and cultured for 24 h. The cells then were treated with the indicated concentration of DHT or adiol. The cells were lysed with 200 μ l hypotonic buffer [20 mM Tris-HCl (pH 7.6), 10 mM NaCl, 1 mM MgCl $_2$, and 0.5% NP-40], and the cytosol fraction was removed by centrifugation. The precipitated nuclei were lysed with 100 μ l hypertonic buffer [20 mM Tris-HCl (pH 7.6), 0.42 M NaCl, and 1 mM EDTA], and nuclear protein was extracted. Fifteen μ g of nuclear protein were loaded in each lane of an 8% SDS-polyacrylamide gel, subjected to electrophoresis, and then electrotransferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). The immobilized proteins were incubated with 5000-fold diluted antihuman androgen receptor antibody NH27 (8). The presence of NH27 was identified by 3000-fold diluted antirabbit antibody conjugated with alkaline phosphatase and stained by Immun-blot kit (Bio-Rad). The intensity of AR protein bands was quantitated by NIH image 1.61 after an image of the membrane was scanned into a Macintosh computer (Apple, Cupertino, CA).

Tumorigenesis of LNCaP Cells *in Vivo*. Thirty-six 6-week-old male severe combined immunodeficient mice were castrated 2 days before inoculation of cells. These mice were divided simultaneously into three groups. One group was a control group ($n = 12$). The other two groups were implanted s.c. with a silastic tablet containing 5 mg DHT ($n = 12$) or adiol ($n = 12$). The 2×10^6 cells/mouse were suspended in 50 μ l of DMEM-10% FCS medium and 50 μ l of Matrigel (BD Biosciences, San Jose, CA) and were inoculated s.c. into the right flank lesion on the treated mice using a 29-gauge needle. The tablets were implanted every 4 weeks. Tumor volume was measured every 5 days (length \times width $^2/2$, length $>$ width) as described by Fujita *et al.* (10). After measuring tumor size on day 50 of inoculation, all of the mice were killed; blood was taken for measuring T and adiol concentration; and the weight of prostates and seminal vesicles was measured.

RESULTS

To explore the effect of decreased serum androgen levels on DHT and adiol concentration in prostate tissues, *trans*-urethral resected benign prostate hypertrophy tissues from patients not receiving hormonal treatments and PCa tissues from patients receiving androgen deprivation therapy for 3–6 months before radical prostatectomy were subjected to liquid chromatography-mass spectrometry to measure DHT and adiol levels (Fig. 1). DHT and adiol concentrations in benign prostate hypertrophy tissue were 2.48 ± 0.57 and 2.33 ± 0.58 ng/g, respectively, whereas those in the PCa tissue were 0.619 ± 0.21 and 2.81 ± 0.59 ng/g tissue, respectively. Thus, although androgen deprivation therapy reduces DHT levels in PCa tissue, it does not impact on adiol level. This finding is consistent with the possibility that adiol in PCa tissue after hormone therapy contributes to PCa progression.

To determine whether adiol has an androgenic effect on PCa cells, we compared the effect of adiol to other DHEA metabolites on proliferation of androgen-sensitive LNCaP cells. LNCaP cells were cultured at the different concentrations of DHEA, T, DHT, 4-dione, or adiol for 4 days. Adiol induced the 20% higher LNCaP cell proliferation at a 10-fold lower concentration than T or DHT and between 100- and 1000-fold lower concentration than DHEA or 4-dione (Fig. 2A). Because it is well known that the production of PSA also is induced by androgen, we investigated expression level of PSA mRNA




Fig. 1. Concentration of dihydrotestosterone (DHT) and androstenediol (adiol) in benign prostate hypertrophy (BPH) and prostate cancer (PCa) tissue after hormone therapy. Fourteen BPH tissues from patients who did not undergo hormone therapy and 12 PCa tissues from patients who were subjected to neoadjuvant hormone therapy were collected by open surgery. The concentrations of DHT and adiol were measured with high-performance liquid chromatography. The data are presented as the mean of triplicate measurements; bars, \pm SE.

in LNCaP cells treated with various androgens for 12 h (Fig. 2B and C). More than 10^{-9} M DHT increased PSA mRNA level, and 4-dione and DHEA hardly increased it. In contrast, even low adiol concentration (10^{-11} M) increased PSA mRNA level to two to four times of control. These results suggest that adiol itself has the ability to induce LNCaP cell proliferation and PSA mRNA expression because low adiol concentration cannot be converted to high T or DHT concentration that stimulates proliferation. To evaluate further the direct ability of adiol as androgen, we transfected LNCaP cells with a luciferase reporter plasmid (pGLPSAp5.8) driven by 5.8 kb of the PSA promoter that includes androgen response elements and compared induction of the promoter by DHT, T, adiol, 4-dione, and DHEA. Adiol at 10^{-10} M induced PSA promoter activity by 28-fold as opposed to 2-fold by DHT or T at equimolar levels (Fig. 3A). Furthermore, 10^{-10} M 4-dione or DHEA did not induce PSA promoter activity. This result, combined the ability of adiol to induce LNCaP cell proliferation and PSA production, suggests that adiol itself has strong androgenic activity in LNCaP cells.

To determine if adiol mediates its activity through the AR, we examined if an antiandrogen, bicalutamide, can block adiol's ability to stimulate the PSA promoter. LNCaP cells were transfected with pGLPSAp5.8 and treated with DHT or adiol in the presence of various concentrations of bicalutamide. Bicalutamide blocked the activity of DHT and adiol in a dose-dependent manner, although a higher concentration of bicalutamide was necessary to block adiol (Fig. 3B). This result demonstrates that adiol's ability to activate the PSA promoter requires the AR and that adiol has strong androgenic activity in LNCaP cells.

To ensure the results were not specific to LNCaP cells, we tested whether adiol is androgenic in the PC-3 PCa cell line. PC-3 cells do not express the AR, so we cotransfected wild-type AR expression plasmid (pCMV-AR) and the pGLPSAp5.8 reporter into PC-3 PCa cells and compared the androgenic ability among DHT, 4-dione, DHEA, and adiol. In contrast to the results using LNCaP cells, DHT induced greater PSA promoter activity than adiol in PC-3 cells (Fig. 4). Additionally, 4-dione had weak androgenic activity, and DHEA did not induce PSA promoter activity.

One difference that could account for the discordant results between the two cell lines is that the AR in the LNCaP cells is mutated (a mutation at the position of 877 amino acid), and we had transfected PC-3 cells with the wild-type AR (11). The 877 mutation has been

shown to confer promiscuity of the AR's response to steroids. Therefore, we postulated that the increased responsiveness to adiol in LNCaP cells compared with PC-3 cells transfected with wild-type AR was the result of the LNCaP cell's mutated AR. To test this possibility, we cotransfected PC-3 cells with the pGLPSAp5.8 reporter and either a wild-type AR or a mutated AR expression plasmid (pCMV-ARmut877), which encodes the same AR mutation found in LNCaP cells, and compared DHT's and adiol's effects on PSA promoter




Fig. 2. Effect of androstenediol (adiol) on LNCaP cells. A, 24 h after 1×10^5 LNCaP cells were seeded, cells were treated with the indicated concentration of adiol, dihydrotestosterone (DHT), testosterone, androstenedione (4-dione), or dehydroepiandrosterone (DHEA) and cultured for 4 days. The cells then were counted by a hemocytometer. The medium was changed every 2 days, and the reagents were added at the same time. B, regulation of prostate-specific antigen (PSA) mRNA by androgens. Twenty-four h after LNCaP cells were seeded, cells were treated with the indicated concentrations of adiol, DHT, 4-dione, or DHEA and cultured for 12 h. The cells then were harvested, and total RNA was extracted. Reverse transcription-PCR analysis of PSA mRNA was performed according to the "Materials and Methods." C, the amplified products from PSA mRNA in B were quantitated by NIH image 1.61 and normalized by GAPDH. The data are presented as the mean of triplicate experiments; bars, \pm SD.




Fig. 3. Effect of androgens on prostate-specific antigen (PSA) promoter in LNCaP cells. A, 2×10^5 LNCaP cells were transfected with $0.5 \mu\text{g}$ pGLPSAp5.8, $1.5 \mu\text{g}$ pBluescript, and $0.2 \mu\text{g}$ β -gal expression plasmid. Twenty-four h after transfection, cells were treated with the indicated concentrations of androstenediol (*adiol*), dihydrotestosterone (*DHT*), testosterone, androstenedione (*4-dione*), or dehydroepiandrosterone (*DHEA*) for 24 h, and luciferase activities then were measured. The data were normalized with β -galactosidase activity. B, effect of bicalutamide on adiol activity in LNCaP cells. The 2×10^5 LNCaP cells were transfected with $0.5 \mu\text{g}$ pGLPSAp5.8, $1.5 \mu\text{g}$ pBluescript, and $0.2 \mu\text{g}$ β -gal expression plasmid. Twenty-four h after transfection, cells were treated with 10^{-9} M adiol or DHT and the indicated concentrations of bicalutamide for 24 h, and luciferase activities then were measured. The data were normalized with β -galactosidase activity.




Fig. 4. Effect of androstenediol (*adiol*) on PC-3 cells transfected with wild androgen receptor (*AR*). The 2×10^5 PC-3 cells were transfected with $0.5 \mu\text{g}$ pGLPSAp5.8, $1.0 \mu\text{g}$ pCMV-hAR, $0.5 \mu\text{g}$ pBluescript, and $0.2 \mu\text{g}$ β -gal expression plasmid. Twenty-four h after transfection, cells were treated with the indicated concentrations of adiol, dihydrotestosterone (*DHT*), androstenedione (*4-dione*), or dehydroepiandrosterone (*DHEA*) for 24 h, and luciferase activities then were measured. The data were normalized with β -galactosidase activity. The data are presented as the mean of triplicate experiments; bars, \pm SD.

activity in the transfected cells. DHT (10^{-10} M) activated the PSA promoter \sim 50-fold in PC-3 cells transfected with wild-type AR, whereas adiol (10^{-10} M)-mediated activation of the PSA promoter was 82% less than that of DHT (Fig. 5; columns 1–3). DHT-mediated induction of the PSA promoter in PC-3 cells transfected with the mutated AR was decreased by 80% compared with that in the PC-3 cells transfected with wild-type AR (Fig. 5; columns 1–6). However, adiol-mediated induction of the PSA promoter activity was the same in PC-3 cells transfected with either the wild-type or mutated AR (Fig. 5; column 5 versus column 6). Moreover, DHT- and adiol-mediated induction of the PSA promoter was similar in the PC-3 cells transfected with the mutant AR. This latter result, combined with the earlier result that adiol induces greater activation of the PSA promoter than DHT in LNCaP cells, indicates that adiol-induced androgenic activity in LNCaP cells is stimulated by some factors, such as AR coactivators, that are not active in PC-3 cells.

ARA70 is an AR coactivator that has been shown to enhance DHT- and adiol-mediated AR activation in the DU145 PCa cell line transfected with wild-type AR or mutant AR (5). Therefore, we investigated whether ARA70 contributed to adiol-induced PSA promoter activity. Contrary to our expectation, ARA70 inhibited DHT-induced PSA promoter activity by 43% when ARA70 expression plasmid was cotransfected with wild-type AR into PC-3 cells (Fig. 5; column 2 versus column 8). Moreover, ARA70 inhibited adiol-induced PSA promoter activity by 63% (Fig. 5; column 3 versus column 9). In the presence of the mutated AR, ARA70 enhanced DHT- and adiol-induced PSA promoter activity by 155% and 148%, respectively (Fig. 5; columns 5 and 6 versus columns 11 and 12). The observation that ARA70 enhanced equally DHT- and adiol-mediated PSA promoter activity in the presence of mutated AR demonstrates that ARA70 does not account for the greater androgenic action of adiol compared with DHT in LNCaP cells.

To determine if ligand binding to the AR accounts for adiol's greater androgenic activity in LNCaP cells compared with DHT, we next compared the affinity of adiol and DHT for the mutant AR. DHT bound the mutant AR in LNCaP cells bound with high affinity (Fig. 6A; $K_d = 0.58$ nM), whereas adiol bound the mutant AR with one-third of the affinity of DHT (Fig. 6B; $K_d = 1.90$ nM). The observation that the affinity of adiol for AR was less than that of DHT demonstrates that affinity to the AR cannot account for the greater androgenic action of adiol compared with DHT in LNCaP cells.

We investigated next other mechanisms through which adiol induced AR activity. Nuclear hormone receptors are localized generally in the cytoplasm until ligand binding induced nuclear translocation. After we transfected PC-3 cells with wild AR and mutant AR expression plasmid, we treated the cells with 10^{-9} M DHT and adiol for 6 h and extracted nuclear protein. The level of nuclear wild and mutant AR protein then was investigated (Fig. 7A). DHT increased the level of nuclear wild AR (4.5-fold of control) more than adiol (1.5-fold of control). When PC-3 cells were transfected with mutant AR, DHT increased the level of nuclear mutant AR 3.3-fold, whereas nuclear mutant AR level was almost the same, irrespective of AR mutation




Fig. 5. Effect of androgen receptor (*AR*) mutation and ARA70 on androstenediol (*adiol*) activity in PC-3 cells. The 1×10^5 PC-3 cells were transfected with $0.5 \mu\text{g}$ pGLPSAp5.8, $0.25 \mu\text{g}$ pCMV-hAR or pCMV-hARmut877, $1.25 \mu\text{g}$ pSG5 or pSG5ARA70, and $0.2 \mu\text{g}$ β -gal expression plasmid. Twenty-four h after transfection, cells were treated with the indicated concentrations of 10^{-10} M adiol or dihydrotestosterone (*DHT*) for 24 h, and luciferase activities then were measured. The data were normalized by β -galactosidase activity. The data are presented as the mean of three experiments; bars, \pm SD.




Fig. 6. Scatchard analysis of dihydrotestosterone (DHT) and androstenediol (adiol) binding to androgen receptor (AR) in LNCaP cells (not the wild-type AR). A, [^3H]DHT binding to wild-type AR ($K_d = 0.58$ nM). B, [^3H]adiol binding to mutant AR ($K_d = 1.90$ nM).




Fig. 7. Nuclear androgen receptor (AR) expression in PC-3 cells transfected with AR and LNCaP cells. Nuclear proteins were extracted as described in "Materials and Methods" and loaded on an 8% SDS-polyacrylamide gel for Western blot analysis. After protein was transferred to polyvinylidene difluoride membrane, and NH27 anti-AR antibody was used for detection of M_r 110,000 AR. Band density was measured by NIH image 1.62. The data are presented as mean. A, 7×10^5 PC-3 cells were transfected with $4 \mu\text{g}$ pCMV-hAR or pCMV-hARmut877 as described in Fig. 4. One day after transfection, cells were cultured in the absence (c) or presence of 1×10^{-9} M dihydrotestosterone (DHT) (d) or androstenediol (adiol) (a) for 6 h and harvested. B, LNCaP cells were cultured for 12 h in the presence of indicated concentration of DHT or adiol and harvested.

(1.6-fold). This result almost was coincident with the result of PC-3 with wild AR or mutant AR (Fig. 4 and Fig. 5). We also investigated the level of nuclear AR protein in LNCaP cells treated with DHT and adiol. Treatment of 10^{-10} M adiol for 12 h induced a 3.5-fold nuclear AR protein level increase in LNCaP cells compared with only a 1.5-fold increase induced by equimolar levels of DHT (Fig. 7B). This result suggests that adiol's ability to induce AR translocation contributes to adiol's ability to promote a greater androgenic response than DHT.

Because adiol functions as a strong androgen in LNCaP cells *in vitro*, we investigated whether this activity occurred *in vivo*. Levels of the T precursors DHEA and adiol are low in rodents (12). Mice are good models to use to manipulate these levels. After male severe combined immunodeficient mice were castrated, they were divided into three groups: no treatment, adiol-treated, and T-treated groups. Then 2×10^6 LNCaP cells were implanted in these

mice. Twenty days after inoculation of LNCaP cells, tumors were detected in 0 of 12, 6 of 12, and 1 of 11 of the no treatment, adiol-implanted, and T-implanted mice, respectively (Fig. 8A). At 50 days, tumors were detectable in the no treatment group (3 of 12), and there was no significant difference between the castrated mice and the DHT-treated mice. However, tumors in the adiol-treated mice were significantly larger than those in the other two groups (Fig. 8A). Fifty days after inoculation of LNCaP cells, the mice were killed, and weights of the ventral prostate and seminal vesicle were measured (Fig. 8B). The weights of the prostate and seminal vesicle in the castrated mice were 14.0 and 11.6 mg, respectively, and those in T-treated mice were 169.8 mg and 161.6 mg, respectively. However, adiol implantation induced only a slight increase in the prostate and seminal vesicle weights compared with the castrated group (28.6 mg and 17.4 mg, respectively). We also examined the serum T level in all of the mice and the serum adiol level in the adiol-treated mice. T levels in castrated mice and T-treated mice were <0.1 nM and 31 nM (data not shown). Growth curve of LNCaP cells by T *in vitro* shows a biphasic pattern: high concentration of T causes inhibition of LNCaP cell proliferation (Fig. 2A). Because T level in T-treated mice was relatively high compared with the concentration of T promoting proliferation of LNCaP *in vitro*, it is believed that the tumorigenesis of LNCaP cells was reduced by high T concentration. Concentration of T and adiol in adiol-treated severe combined immunodeficient mice was 0.11 nM and <3.4 nM, respectively (data not shown). Taken together, the observation that adiol stimulated LNCaP growth but not prostate and seminal vesicle growth suggests that adiol has a strong effect on LNCaP cells expressing a mutated AR without conversion to T as opposed to tissues expressing a wild-type AR.

DISCUSSION

The major androgenic product secreted from the adrenal gland is DHEA. We have demonstrated recently that the major DHEA metabolite formed in human prostate tissue is adiol (4). Our observation that adiol exists in PCa tissue after hormone therapy, as opposed to the decrease of DHT that occurs, is consistent with the possibility that adiol plays an important role in PCa progression after hormone therapy. This is supported additionally by the observation that adiol activates a mutated AR.

The presence of androgens in prostate tissue after androgen deprivation




Fig. 8. Tumorigenesis of LNCaP cells in severe combined immunodeficient mice. A total of 2×10^6 cells of LNCaP cells were inoculated s.c. in severe combined immunodeficient mice that were castrated and had either castration (cast) alone, testosterone, or androstenediol (adiol) implants. A, tumors were measured from day 20 to day 50 after inoculation. B, after measuring tumor size on day 50 of inoculation, all of the mice were killed; the blood was taken; and the weight of prostate and seminal vesicles (SV) was measured. Data are presented as the mean; bars, \pm SE.

vation provides a mechanism through which the AR can be activated after therapy. Our results that DHT levels decrease by 75% are somewhat in conflict with a previous report that demonstrated androgen levels in PCa tissue decrease by only 50–60% after castration (13). Perhaps methodologies account for these differences. Geller *et al.* (14) described that adrenal androgens DHEA and 4-dione contribute one-fifth to one-sixth of total DHT in prostate tissue and might contribute significantly to the hormone-dependent PCa cells in at least 10% of patients. In the present study, 4-dione and DHEA did not stimulate LNCaP cell proliferation and PSA mRNA expression, and 4-dione had weak androgenic activity to induce PSA promoter in PC-3 cells transfected with wild AR, although these cells might not have enough converting activity from 4-dione to DHT. Once AR in PCa has mutation during hormone therapies, residual adiol, even at low concentration, in prostate tissue also may contribute to relapse of PCa and residual DHT.

The mechanism that maintains adiol levels in PCa tissues after androgen deprivation is not known. Conversion of DHEA to adiol is the only freely reversible reaction in steroid metabolism. To date, five human 17β -hydroxysteroid dehydrogenases (HSDs) have been characterized fully, each showing oxidation or reduction preferences (15). Type 3 17β -HSD converts DHEA to adiol, and type 2 17β -HSD converts adiol to DHEA. Koh *et al.* (16) demonstrated that the expression levels of the type 3 17β -HSD gene in PCa tissue were significantly higher than in nonmalignant tissues and that expression of type 2 17β -HSD in PCa was significantly lower than in nonmalignant tissues. This result suggests that a part of DHEA in prostate tissue is converted to adiol but that the reverse reaction occurs at a limited level in PCa tissue. This finding may account for the continued presence of adiol in PCa tissue after castration.

Fenton *et al.* (17) demonstrated that LNCaP-type AR mutant is similar or less sensitive to 4-dione than wild-type AR. Our data are similar to those reported in their article. In contrast, adiol stimulated LNCaP cells proliferation, PSA mRNA expression, and PSA promoter activity at lower concentration. This is the first report of this phenomenon to our knowledge. They also demonstrated that 100 nM bicalutamide blocked the effect of DHT and 4-dione on androgen response element in CV-1 cells transfected with mutant AR (17). In our study, 100 nM bicalutamide inhibited partially adiol's activity in LNCaP cells. Because adiol has strong androgenic activity even at low concentration in LNCaP cells, higher bicalutamide concentration was necessary to inhibit adiol activity.

We hypothesized that one of mechanisms by which adiol activates mutant AR in LNCaP cells is by enhancing the AR to bind to coactivators. Our results that ARA70 increased PSA promoter activity induced by adiol, albeit slightly, are consistent with the previous reports that describe the AR coactivator ARA70 increased adiol-induced mouse mammary tumor virus promoter activity in DU-145 cells transfected with wild-type AR or mutant AR (5). In the current report, we observed that this induction was not specific to adiol because the same action was found when DHT was used. However, we cannot deny that ARA70 and other coactivators may act cooperatively.

An unexpected finding was that ARA70 reduced adiol-induced PSA promoter activity in the presence of wild-type AR but not mutant AR. This novel finding suggests that a steroid receptor cofactor can act as a coactivator or a corepressor depending on the state (*i.e.*, wild-type *versus* mutant) of the nuclear hormone receptor.

Because there are many other nonspecific and specific AR coactivators, it is necessary to investigate them and ARA70. AR coactivators should be expressed more in LNCaP cells because adiol-induced androgenic activity in LNCaP cells was much higher than in PC-3

cells. We examined previously the expression level of ARA55, SRC1, ARA54, TIF2, and RAC3 mRNA. However, none of them expressed more in LNCaP cells than in PC-3 cells (18). These data suggest that at least other coactivators may be involved in adiol-induced androgenic activity in LNCaP cells.

Nuclear import of nuclear hormone receptors is mediated through a well-characterized nuclear location signal sequence, NL1, adjacent to the receptor DNA binding domain, and a second uncharacterized motif, NL2, which overlaps with the ligand binding domain (19). Several proteins, such as β -catenin, filamin, importin, Ran, and nuclear transport factor 2, mediate the translocation (20–22). The observation that adiol increased AR import into nuclei more than DHT did in LNCaP cells suggests that adiol facilitates the interaction between mutant AR and these proteins related to nuclear transport.

In conclusion, we identified adiol is present in PCa tissue after androgen deprivation therapy at the same levels of benign prostate hypertrophy tissue without hormone treatment. Furthermore, low concentration of adiol can stimulate proliferation of PCa with mutated AR. Taken together, this provides the opportunity for adiol to promote progression of PCa that has developed a mutated AR during androgen deprivation therapy and 25–40% of DHT in PCa tissue after hormone therapies. Several trials using ketoconazole, which inhibits adrenal androgen synthesis, have been carried out recently for patients with advanced PCa, which progresses after androgen deprivation (23). The effect of inhibition of adrenal androgen synthesis has been recognized. However, a severe toxicity also has been observed because of reduction of other steroids. Our results suggest that in addition to antiandrogens, such as bicalutamide, inhibitors that block selectively synthesis of DHEA and adiol may be useful for extending the period when PCa is sensitive to androgen deprivation therapy without severe side effects.

REFERENCES

- Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. *CA - Cancer J. Clin.*, 53: 5–26, 2003.
- Takeda, H., Akakura, K., Masai, M., Akimoto, S., Yatani, R., and Shimazaki, J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. *Cancer (Phila.)*, 77: 934–940, 1996.
- Belanger, A., Brochu, M., and Cliche, J. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. *J. Clin. Endocrinol. Metab.*, 62: 812–815, 1986.
- Mitamura, K., Nakagawa, T., Shimada, K., Namiki, M., Koh, E., Mizokami, A., and Honma, S. Identification of dehydroepiandrosterone metabolites formed from human prostate homogenate using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry. *J. Chromatogr. A.*, 961: 97–105, 2002.
- Miyamoto, H., Yeh, S., Lardy, H., Messing, E., and Chang, C. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. *Proc. Natl. Acad. Sci. USA*, 95: 11083–11088, 1998.
- Shibata, Y., Ito, K., Suzuki, K., Nakano, K., Fukabori, Y., Suzuki, R., Kawabe, Y., Honma, S., and Yamanaka, H. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. *Prostate*, 42: 45–55, 2000.
- Green, B., and Leake, R. E. *Steroid Hormones: Practical Approach*, Vol. 1087, pp. 67–93. Oxford: IRL Press, 1987.
- Mizokami, A., Saiga, H., Matsui, T., Mita, T., and Sugita, A. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. *Endocrinol. Jpn.*, 39: 235–243, 1992.
- Mizokami, A., Gotoh, A., Yamada, H., Keller, E. T., and Matsumoto, T. Tumor necrosis factor- α represses androgen sensitivity in the LNCaP prostate cancer cell line. *J. Urol.*, 164: 800–805, 2000.
- Fujita, H., Koshida, K., Keller, E. T., Takahashi, Y., Yoshimoto, T., Namiki, M., and Mizokami, A. Cyclooxygenase-2 promotes prostate cancer progression. *Prostate*, 53: 232–240, 2002.
- Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. *Biochem. Biophys. Res. Commun.*, 173: 534–540, 1990.

12. Wichmann, U., Wichmann, G., and Krause, W. Serum levels of testosterone precursors, testosterone and estradiol in 10 animal species. *Exp. Clin. Endocrinol.*, 83: 283–290, 1984.
13. Labrie, F. Endocrine therapy for prostate cancer. *Endocrinol. Metab. Clin. North Am.*, 20: 845–872, 1991.
14. Geller, J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. *Semin. Oncol.*, 12: 28–35, 1985.
15. Labrie, F., Luu-The, V., Lin, S. X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., and Belanger, A. Intracrinology: role of the family of 17 α -hydroxysteroid dehydrogenases in human physiology and disease. *J. Mol. Endocrinol.*, 25: 1–16, 2000.
16. Koh, E., Noda, T., Kanaya, J., and Namiki, M. Differential expression of 17 β -hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. *Prostate*, 53: 154–159, 2002.
17. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Buble, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. *Clin. Cancer Res.*, 3: 1383–1388, 1997.
18. Fujimoto, N., Mizokami, A., Harada, S., and Matsumoto, T. Different expression of androgen receptor coactivators in human prostate. *Urology*, 58: 289–294, 2001.
19. Savory, J. G., Hsu, B., Laquian, I. R., Giffin, W., Reich, T., Hache, R. J., and Lefebvre, Y. A. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. *Mol. Cell Biol.*, 19: 1025–1037, 1999.
20. Pawlowski, J. E., Ertel, J. R., Allen, M. P., Xu, M., Butler, C., Wilson, E. M., and Wierman, M. E. Liganded androgen receptor interaction with β -catenin. Nuclear colocalization and modulation of transcriptional activity in neuronal cells. *J. Biol. Chem.*, 277: 20702–20710, 2002.
21. Ozanne, D. M., Brady, M. E., Cook, S., Gaughan, L., Neal, D. E., and Robson, C. N. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. *Mol. Endocrinol.*, 14: 1618–1626, 2000.
22. Smith, A., Brownawell, A., and Macara, I. G. Nuclear import of Ran is mediated by the transport factor NTF2. *Curr. Biol.*, 8: 1403–1406, 1998.
23. Richie, J. P. Anti-androgens and other hormonal therapies for prostate cancer. *Urology*, 54: 15–18, 1999.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor

Atsushi Mizokami, Eitetsu Koh, Hiroshi Fujita, et al.

Cancer Res 2004;64:765-771.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/64/2/765>

Cited articles This article cites 22 articles, 5 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/64/2/765.full#ref-list-1>

Citing articles This article has been cited by 28 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/64/2/765.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/64/2/765>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.